The American Journal of Surgery
Volume 196, Issue 2 , Pages 155-159 , August 2008

Effects of percutaneous ethanol injection therapy on subsequent parathyroidectomy

  • Han-Hsiang Chen, M.D.

      Affiliations

    • Department of Nephrology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan
    • Nursing and Management College, Mackay Medicine, Taipei, Taiwan
    • National Taipei College of Nursing, Taipei, Taiwan
    • Corresponding Author InformationCorresponding author. Tel.: +011-886-2-25433535; fax: +1-886-2-25433642.
    • ,
  • Ming-Tsung Hsu, M.D.

      Affiliations

    • Department of Nephrology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan
    • ,
  • Chih-Jen Wu, Ph.D.

      Affiliations

    • Department of Nephrology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan
    • Nursing and Management College, Mackay Medicine, Taipei, Taiwan
    • Graduate Institute of Medical Science, Taipei Medical University, Taipei, Taiwan
    • ,
  • Yu-Wei Chen, M.D.

      Affiliations

    • Department of Nephrology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan
    • ,
  • Tsen-Long Yang, M.D.

      Affiliations

    • Department of General Surgery, Mackay Memorial Hospital, Taipei, Taiwan

Received 22 March 2007 ,Revised 12 June 2007

References 

  1. Fukagawa M, Fukuda N, Yi H, et al. Resistance to calcitriol as a cause of parathyroid hyperfunction in chronic renal failure. Nephrol Dial Transplant. 1995;10:316–319
  2. Fukuda N, Tanaka H, Tominaga Y, et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993;92:1436–3
  3. Llach F, Yudd M. Pathogenic, clinical, and therapeutic aspects of secondary hyperparathyroidism in chronic renal failure. Am J Kidney Dis. 1998;32(suppl):S3–S12
  4. Solbiati L, Giangrande A, De Pra L, et al. Percutaneous ethanol injection of parathyroid tumors under US guidance: treatment for secondary hyperparathyroidism. Radiology. 1985;155:607–610
  5. Fletcher S, Kanagasundaram NS, Rayner HC, et al. Assessment of ultrasound guided percutaneous ethanol injection and parathyroidectomy in patients with tertiary hyperparathyroidism. Nephrol Dial Transplant. 1998;13:1311–1317
  6. Giangrande A, Catiglioni A, Solbiati L, et al. Ultrasound guided percutaneous fine-needle ethanol injection into parathyroid glands in secondary hyperparathyroidism. Nephrol Dial Transplant. 1992;7:412–421
  7. Kakuta T, Fukagawa M, Fujisaki T, et al. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients. Am J Kidney Dis. 1999;33:109–119
  8. De Barros Gueiros JE, Chammas MC, Gerhard R, et al. Percutaneous ethanol (PEIT) and calcitrol (PCIT) injection therapy are ineffective in treating severe secondary hyperparathyroidism. Nephrol Dial Transplant. 2004;19:657–663
  9. Tanaka R, Kakuta T, Fujisaki T, et al. Long-term (3 years) prognosis of parathyroid function in chronic dialysis patients after percutaneous ethanol injection therapy guided by color Doppler ultrasonography. Nephrol Dial Transplant. 2003;18(suppl 3):iii58–iii61
  10. Yamamoto H, Katoh N, Takeyama H, et al. Surgical verification of percutaneous maxacalcitol injection therapy on enlarged parathyroid glands in chronic dialysis patients. Nephrol Dial Transplant. 2003;18(suppl 3):iii50–iii2
  11. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(suppl):S1–S201
  12. Katoh N, Nakayama M, Shigematsu T, et al. Presence of sonographically detectable parathyroid glands can predict resistance to oral pulse-dose calcitriol treatment of secondary hyperparathyroidism. Am J Kidney Dis. 2000;35:465–468
  13. Akerstrom G, Malmaeus J, Grimelius L, et al. Histological changes in parathyroid glands in subclinical and clinical renal disease (An autopsy investigation). Scand J Urol Nephrol. 1984;18:75–84
  14. Tominaga Y, Tanaka Y, Sato K, et al. Histology: pathophysiology and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol. 1997;13:78–86
  15. Fukagawa M, Tominaga Y, Kitaoka M, et al. Medical and surgical aspects of parathyroidectomy. Kidney Int. 1999;73(suppl):S65–S69
  16. Strippoli GF, Palmer S, Tong A, et al. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis. 2006;47:715–726
  17. Fukagawa M, Kitaoka M, Yi H, et al. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron. 1994;68:221–228
  18. Richards ML, Wormuth J, Bingener J, et al. Parathyroidectomy in secondary hyperparathyroidism: Is there an optimal operative management?. Surgery. 2006;139:174–180
  19. Fukagawa M, Kitaoka M, Tominaga Y, et al. Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients. Nephrol Dial Transplant. 2003;18(suppl 3):iii31–iii33
  20. Numano M, Tominaga Y, Uchida K, et al. Surgical significance of supernumerary parathyroid glands in renal hyperparathyroidism. World J Surg. 1998;22:1098–1102

PII: S0002-9610(08)00232-8

doi: 10.1016/j.amjsurg.2007.06.037

The American Journal of Surgery
Volume 196, Issue 2 , Pages 155-159 , August 2008

Article Tools

* Image Usage & Resolution